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562Objectives: Early-stage non–small cell lung cancer (NSCLC) has a high recurrence rate and poor 5-year sur-
vival, particularly if lymph nodes are involved. Our objective was to perform a dose-escalation study to assess
safety and feasibility of intraoperative near-infrared (NIR) fluorescence imaging to identify the first tumor-
draining lymph nodes (ie, sentinel lymph nodes [SLNs] in patients with NSCLC).
Methods:A-dose escalation phase 1 clinical trial assessing real-time NIR imaging after peritumoral injection of
3.8 to 2500 mg indocyanine green (ICG) was initiated in patients with suspected stage I/II NSCLC. Visualization
of lymphatic migration, SLN identification, and adverse events were recorded.
Results: Thirty-eight patients underwent ICG injection and NIR imaging via thoracotomy (n ¼ 18) or thoraco-
scopic imaging (n ¼ 20). SLN identification increased with ICG dose, with fewer than 25% SLNs detected in
dose cohorts of 600 mg or less versus 89% success at 1000 mg or greater. Twenty-six NIRþ SLNs were identified
in 15 patients, with 7 NIRþ SLNs (6 patients) harboring metastatic disease on histologic analysis. Metastatic
nodal disease was never identified in patients with a histologically negative NIRþ SLN. No adverse reactions
were noted.
Conclusions: NIR-guided SLN identification with ICG was safe and feasible in this initial dose-escalation
trial. ICG doses greater than 1000 mg yielded nearly 90% intrathoracic SLN visualization, with the presence
or absence of metastatic disease in the SLN directly correlating with final nodal status of the lymphadenec-
tomy specimen. Further studies are needed to optimize imaging parameters and confirm sensitivity and
specificity of SLN mapping in NSCLC using this promising imaging technique. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and Cardiovascular SurgRegional lymph node status is the most important prognos-
tic indicator in early-stage non–small cell lung cancer
(NSCLC). Although noninvasive preoperative staging using
computed tomographic (CT) and positron emission tomo-
graphic (PET) scans is useful in determining metastatic dis-
ease in nodes greater than 1 cm, these modalities frequently
miss regional lymphatic metastasis.1 Surgical resection and
lymphadenectomy remain the standard, but routine com-
plete lymphadenectomy is reported in only 50% of pa-
tients.2-4 Furthermore, the practice of lymph node
sampling can miss metastatic disease secondary to the
propensity of NSCLC to ‘‘skip’’ to N2 mediastinal nodes
and the lack of in-depth histologic analysis on multiple sam-
pled nodes. Unfortunately, patients with missed metastatic
disease are deemed to have stage I disease and do not re-
ceive adjuvant therapy, which likely contributes to the
nearly 40% incidence of recurrent disease and the 50%
to 60% 5-year survival rate reported for patients initially
identified with early-stage disease.5-8
Compared with other early-stage solid tumors, high re-
currence rates and poor overall survival in early-stage
NSCLC suggest that patients are understaged and/or under-
treated. Poor outcomes may be attributed to inadequate
nodal sampling, skip metastases, and/or inadequateery c September 2013
Abbreviations and Acronyms
CT ¼ computed tomography
FFP ¼ fresh-frozen plasma
H&E ¼ hematoxylin and eosin
HSA ¼ human serum albumin
ICG ¼ indocyanine green
NIR ¼ near infrared
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomographic
SLN ¼ sentinel lymph node
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Shistologic processing for identification of occult metasta-
ses.5-7 Sentinel lymph node (SLN) mapping offers the
benefit of identifying nodes at greatest risk for metastatic
spread, focusing in-depth immunohistochemical analysis
on ‘‘high-risk’’ nodes and decreasing morbidity by local-
izing nodal dissection, and has become the standard of
care in breast cancer and melanoma.9,10 However, SLN
mapping has been unreliable in NSCLC because of
difficult anatomic access to hilar structures and a poor
signal-to-noise ratio, making tracer visualization in anthrac-
tic nodes or identification of radioactive nodes subopti-
mal.11-16 Near-infrared (NIR) imaging has successfully
been used for real-time intraoperative SLN identification
in cancers of the skin, breast, and gastrointestinal tract17-20
and is ideal for in vivo intraoperative imaging because of
low absorption, scatter, and tissue autofluorescence within
the NIR spectrum (700-1000 nm).21 As a result, NIR-
fluorescent lymphatic tracers permit surgical dissection
without distortion of critical anatomy.22 In addition, safety
is increased because laser and radioactivity are not required.
Indocyanine green (ICG) is a common Food and Drug Ad-
ministration–approved intravascular dye that also functions
as an NIR lymphatic fluorophore. Therefore, we hypothe-
sized that NIR lymphatic imaging with ICG may permit
SLN identification in patients with early-stage NSCLC.
This article reports results from the first phase 1 dose-
escalation clinical trial using ICG to assess the safety and
feasibility of NIR-guided SLN identification in patients
with early-stage NSCLC via either an open thoracotomy
imaging platform or a thoracoscopic NIR system.METHODS
Eligibility
After informed consent, a total of 46 patients scheduled to undergo lung
resection for known or suspected lung cancer were enrolled between Feb-
ruary 2009 and February 2013 in this dose-escalation SLN trial approved
by the Dana Farber Cancer Institute Institutional Review Board (Boston,
Mass). Exclusion criteria included younger than 18 years, pregnancy, lac-
tation, and allergy to iodine, shellfish, or ICG. Eight patients were subse-
quently ineligible as the result of subsequent data excluding stage I/II
NSCLC, withdrawal of consent before surgery, or equipment repair
(n ¼ 1). Therefore, 38 patients received an intraoperative peritumoralThe Journal of Thoracic and Cainjection of ICG and underwent NIR-mediated SLNmapping. All study pa-
tients underwent preoperative chest CT and PET/CT scanning, with cervi-
cal mediastinoscopy or endobronchial ultrasound generally performed in
patients with tumors larger than 2 cm, mediastinal lymphadenopathy
(>1-cm lymph nodes), PET avid nodes, or more central tumors. In the cur-
rent study, in which all patients were required to have a negative PET/CT
scan result or a prior negative cervical mediastinoscopy for enrollment, 13
(34%) of the 38 study patients also underwent additional surgical staging
via mediastinoscopy or endobronchial ultrasound before this study.
ICG Preparation
ICG was purchased from Akorn, Inc (IC-GREEN, Decatur, Ill) or di-
rectly from Novadaq Technologies (Bonita Springs, Fla), resuspended in
10 mL sterile saline to yield a stock solution of 3.2 mM, and appropriately
diluted in 50 mL of fresh-frozen plasma (FFP) or 25% human serum albu-
min (HSA; Baxter, Deerfield, Ill) to yield ICG:FFP or ICG:HSA concentra-
tions of 10 mM to 3.2 mM. FFP was used in the initial 18 patients as
a coupling agent for ICG until NIR mapping in other organ systems dem-
onstrated technical equivalence in image quality with HSA, which was
used thereafter to avoid potential infectious risks with FFP exposure.17
NIR Fluorescence Imaging Systems
Real-time NIR fluorescence images were obtained using either the
FLARE open surgery imaging system21 or a 10-mm thoracoscopic NIR
camera supplied by Novadaq Technologies. Each system captures both
white light and NIR fluorescence images and simultaneously displays these
images in real time. Video output contains 3 images of the surgical field:
a white light image (ie, color video as seen by the human eye), a pure
NIR image (a black-and-white image), and a merged NIR pseudocolored
(green) image superimposed on the white light video image. This approach
avoids obscuring the surgical field with visible contrast agents while pro-
viding the ability to correlate NIR images with surgical anatomy.Intraoperative NIR Imaging Technique in Patients
With Suspected Lung Cancer
The basic technique for intrathoracic NIR imaging has been previously
described, although success with low-dose ICG has been limited.23 Based
on preclinical trials in large animals and these earlier studies,24 the initial
ICG dose was 3.8 mg and increased to 2500 mg during this dose-escalation
trial. Briefly, after induction of anesthesia and surgical incision(s), ICG:FFP
or ICG:HSA formulations were injected using NIR guidance into the lung
parenchyma using a 25-gauge needle in 4 sites surrounding the suspected
lung cancer. Before tumor excision, the lung was ventilated for 5 minutes
to facilitate ICGmigration within the lymphatic channels to the SLN. Visu-
alization of lymphatic pathways and SLN in situ was attempted using NIR
imaging via the open platform, when patients underwent surgical resection
via a thoracotomy, or the minimally invasive NIR thoracoscope, for video-
assisted thoracoscopic surgery procedures. The location of the visualized
SLN was noted, and the known or suspected lung cancer was resected in
the standardmanner, as determined by the surgeon. If benign, no further sur-
gery was performed and the SLN was left in situ, although the location was
recorded. If the tumor was malignant, the NIR-identified SLNwas resected,
followed by lymphadenectomy, as determined by the surgeon, with subse-
quent imaging of the lymphadenectomy specimen and the surgical field to
ensure that all SLNs were identified and removed. The SLN identification
rate, time to identification, number of SLNs identified, SLN station, and pa-
thology were recorded. Post-resection images of all specimens and the oper-
ative site were stored for subsequent review to confirm NIR status. SLNs
were fixed in formalin and embedded in paraffin for standard hematoxylin
and eosin (H&E) analysis. If sufficient tissuewas available after routine clin-
ical analysis, in-depth analysis of the NIR-identified SLNs for micrometa-
static disease was performed, which involved transverse sectioning of the
paraffin-embedded SLN at 1.5-mm intervals with H&E analysis ofrdiovascular Surgery c Volume 146, Number 3 563
TABLE 1. Dose-escalation of ICG and successful intraoperative sentinel lymph node mapping in patients with NSCLC
Patient no.
Location of
tumor
Tumor
size, cm
Type of surgical
resection Tumor pathology ICG dose, mg SLN found? SLN node station*
1 RUL 1.2 Segmentectomy Adenocarcinoma 3.8 No –
2 RUL 1.0 Wedge resection Adenocarcinoma 3.8 No –
3 LUL 1.3 Wedge resection Metastatic prostate cancer 3.8 Noy –
4 LUL 1.1 Wedge resection Adenocarcinoma 3.8 No –
5 RUL 7.0 Lobectomy Adenocarcinoma 7.75 No –
6 LUL 6.0 Lobectomy Adenocarcinoma 7.75 Yes 4L
7 LLL 2.0 Lobectomy Adenocarcinoma 7.75 No –
8 RML 3.0 Lobectomy Adenocarcinoma 7.75 No –
9 RLL 2.2 Lobectomy Adenocarcinoma 7.75 No –
10 RLL 3.8 Segmentectomy Adenocarcinoma 15.5 No –
11 LUL 2.1 Lobectomy Adenocarcinoma 15.5 No –
12 L hilum 3.7 Pneumonectomy Squamous cell 100 No –
13 RUL 1.3 Segmentectomy Squamous cell 100 Yes 10.1R, 10.2R, 10.3R
14 RUL 1.7 Lobectomy Large cell 100 Yes 11R
15 LLL 1.5 Segmentectomy Metastatic melanoma 200 Noy –
16 RUL 2.3 Lobectomy Adenocarcinoma 200 Yes 10.1R
17 LUL 2.4 Wedge resection Adenocarcinoma 200 No –
18 RLL 3.0 Lobectomy Squamous cell 400 No –
19 RLL 1.4 Wedge resection Nocardiosis 400 Noy –
20 LUL 0.9 Lobectomy Adenocarcinoma 400 No –
21 RML 0.3 Segmentectomy Adenocarcinoma 600 No –
22 LUL 0.6 Wedge resection Adenocarcinoma 600 No –
23 LUL 1.6 Segmentectomy Adenocarcinoma 600 Yes 10L, 11L
24 RLL 4.0 Wedge resection Adenocarcinoma 800 Yes 9R
25 RUL 3.2 Lobectomy Adenocarcinoma 800 Yes 10.1R, 11R
26 RUL 2.0 Wedge resection Adenocarcinoma 800 No –
27 RLL 1.1 Wedge resection Adenocarcinoma 800 No –
28 RUL – Wedge resection Necrotizing granuloma 800 Noy –
29 RUL 1.2 Wedge resection Sarcomatoid carcinoma 1000 Yes 4R
30 LUL 2.6 Lobectomy Adenocarcinoma 1000 Yes 9.1L, 10.1L
31 RUL 0.9 Wedge resection Lymphoma 1000 Technical
failurez
–
32 LUL 6.5 Lobectomy Adenocarcinoma 1000 Yes 5, 10.1L
33 RML 1.5 Lobectomy Adenocarcinoma 1000 No –
34 LLL 1.0 Segmentectomy Adenocarcinoma 1000 Yes 10.1L
35 RUL 1.1 Wedge resection Adenocarcinoma 2500 Yes 4.1R, 10.1R
36 RML 2.4 Lobectomy Adenocarcinoma 2500 Yes 4R, 10.1R, 10.2R
37 LUL 2.0 Lobectomy Squamous cell 2500 Yes 10.1L, 10.2L
38 RLL 2.9 Lobectomy Adenocarcinoma 2500 Yes 11.1R, 11.2R
Italics denote doses<800 mg. Bold indicates those patients in which a sentinel lymph node was identified via NIR imaging. ICG, Indocyanine green; NSCLC, non–small cell lung
cancer; SLN, sentinel lymph node; RUL, right upper lobe; LUL, left upper lobe; LLL, left lower lobe; RML, right middle lobe; L, left;R, right. *Nodes retrieved from the same nodal
station (x) are labeled in sequential order as x.1, x.2, to maintain individual identity. yNo nodes were removed given the finding of nonlung cancer pathology. zAfter injection,
there was a camera malfunction with loss of video display prior to imaging.
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of the step sections forAE1/AE3cytokeratin, cytokeratin 7, and thyroid tran-
scription factor 1.Micrometastaseswere defined as tumor aggregates of 0.2
to 2mmand isolated tumor cells or clusters if those aggregatesmeasured less
than 0.2 mm.
RESULTS
Patient Demographics
A total of 25 female and 13 male patients, for a total of
38 patients with suspected stage I/II NSCLC, underwent
peritumoral injection of ICG at surgical resection.
The median age was 64.9  10.3 years. There was564 The Journal of Thoracic and Cardiovascular Surga predominance of right and left upper lobe tumors, al-
though tumors in all 5 anatomic lobes were represented.
Lung resections included wedge, segmentectomy, lobec-
tomy, or pneumonectomy, as determined by the attending
surgeon, with most tumors removed via lobectomy or seg-
mentectomy. Tumor location, extent of surgical resection
performed, and pathology of the resected lung nodule for
each patient are listed in Table 1. A total of 33 patients
had NSCLC, with adenocarcinoma representing more
than 80% of all tumors resected, regardless of the lobe
of origin.ery c September 2013
FIGURE 1. Sentinal lymph node (SLN) identification. A dose-dependent
increase in SLN identification is demonstrated as a function of indocyanine
green (ICG) dose from 3.8 to 2500 mg. The SLN identification rate was
100% in the highest cohort. RUL, Right upper lobe; RML, right middle
lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
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Escalation
NIR imaging using ICG was performed in a total of 38
patients over an ICG dose range of 3.8 to 2500 mg. Eighteen
patients underwent intraoperative NIR imaging using an
open imaging system at thoracotomy, and 20 patients under-
went videoscopic exploration and intraoperative NIR imag-
ing using a minimally invasive thoracoscope. For doses of
less than 600 mg, unreliable lymphatic migration and SLN
identification were demonstrated because only 4 (20%) of
20 patients demonstrated positive lymphatic tracking and
SLN identification. However, in each successive cohort of
600, 800, 1000, and 2500 mg, lymphatic migration and
SLN identification improved, with the rate of SLN identifi-
cation increasing from 33% to 40%, 80%, and 100%,
respectively (Figure 1).
NIR-Guided SLN Identification
Of the 38 patients enrolled in the study, 5 did not have
NSCLC and, thus, no SLN dissection or subsequent lym-
phadenectomy was performed. In the 33 patients with
NSCLC and, therefore, available for lymph node analysis,FIGURE 2. Intraoperative real-time identification of sentinel lymph nodes (
migration of indocyanine green is noted in green and progresses from the sit
NIR fluorescent imaging and is shown in green (arrow).
The Journal of Thoracic and Caa total of 26 sentinel lymph nodes were identified intraoper-
atively in 15 patients (Table 1). Figure 2 is an intraoperative
image of lymphatic migration visualized in situ with identi-
fication of the SLN in green. Time from ICG injection to
SLN identification and subsequent removal using NIR im-
aging ranged from 3 to 125 minutes (when resection of
the primary tumor was required to establish NSCLC diag-
nosis before SLN removal could be performed), with
a mean time of 30 minutes. All resected SLNs were imaged
ex vivo to confirm NIR positivity. Figure 3 is an ex vivo
image of an SLN in normal white light, pure NIR, and
a merged pseudocolored (white light-NIR) image highlight-
ing the appearance and the localization of the NIR signal
within the SLN.
After NIR imaging, patients with NSCLC underwent
a radical lymphadenectomy or lymph node sampling at
the surgeon’s discretion, and all specimens were imaged
for any additional NIRþ SLN, of which none was identified
in this study. The average number of lymph node stations
sampled per patient within the resected surgical specimen
was 2.9  2 (ie, hilar, levels 4 and 7), and they were inde-
pendent from prior stations sampled via mediastinoscopy,
endobronchial ultrasound, or SLN mapping. In addition,
the average number of additional nodes harvested per pa-
tient was a minimum of 6.5  5.3, because multiple nodes
from the same station were often not counted separately on
the final pathology report.
The location of the 26 identified NIRþ SLNs in relation to
the primary tumor and injection site is illustrated in
Figure 4. Nineteen of these lymph nodes were identified
in the hilar (n ¼ 14) or interlobar (n ¼ 5) N1 stations. Of
the 7 lymph nodes in the N2 stations, 2 were identified in
the pulmonary ligament (station 9), 1 in the aortopulmonary
window (station 5), and 4 in the superior mediastinum (sta-
tion 4). SLNs from the left upper lobe seemed to be partic-
ularly diverse in their location.Histologic Analysis of NIRþ SLNs
Of the 26 nodes identified with NIR guidance in 15 pa-
tients, 7 SLNs (6 patients) demonstrated evidence ofSLNs) using near-infrared (NIR) fluorescent imaging. A, The lymphatic
e of injection toward the hilum (arrow). B, The SLN is identified using
rdiovascular Surgery c Volume 146, Number 3 565
FIGURE 3. Ex vivo sentinel lymph node (SLN) imaging using near-infrared (NIR) fluorescent imaging. After intraoperative identification and excision of
the SLN, the SLN is imaged ex vivo using NIR imaging to confirm fluorescence. A, White light image of the SLN. B, Pure NIR image demonstrating NIR
fluorescence in white (arrowhead). C, Merged pseudocolored image of the SLN with NIR fluorescence within the SLN shown in green.
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analysis (Table 2). All 7 histologically positive NIRþ SLNs
were located within level 10 or 11 nodal stations. Although
metastatic disease was identified in some patients in addi-
tional lymph nodes within the surgical lymphadenectomy
specimen, it is significant that these nodes were generally
at the same or more proximal lymph node stations, thus sig-
nifying lymphatic spread of metastatic disease beyond the
SLN. Metastatic nodal disease was never identified in pa-
tients with a histologically negative NIRþ SLN. In fact, in
2 of the 6 patients, the only histologically positive node,
including those within the surgical lymphadenectomyFIGURE 4. Lymphatic map of sentinel lymph node (SLN) stations iden-
tified via near-infrared (NIR) image guidance: a total of 26 NIRþ SLNs
were identified in 15 patients. The location of the identified SLNs in rela-
tion to the site of the primary tumor (and injection site) is demonstrated.
RUL, Right upper lobe; LUL, left upper lobe; RML, right middle lobe;
LLL, left lower lobe; RLL, right lower lobe; L, left; R, right.
566 The Journal of Thoracic and Cardiovascular Surgspecimen, was the single SLN identified via NIR imaging.
Interestingly, in-depth immunohistochemical analysis on
7 NIRþ SLNs deemed negative by standard H&E did not
reveal evidence of occult metastatic disease.DISCUSSION
Sentinel lymph node biopsy is a well-established prog-
nostic indicator and important criterion in the staging of ma-
lignant disease for many cancers. However, standard
approaches with blue dye and radioisotopes have not trans-
lated into successful identification of the SLN(s) in patients
with NSCLC. Little and colleagues11 first attempted SLN
biopsy in lung cancer in 1999, with only a 47% success
rate. In 2000, Liptay and colleagues12,13 successfully used
technetium for SLN identification in 87% of patients with
lung cancer; however, these results were not reproducible
in a phase 2 multicenter Cancer and Leukemia Group B
(CALGB) trial that noted SLN identification in only 51%
of patients. Variations of techniques have been attempted,
but results have been unreliable, with poor sensitivity and/
or specificity.11-16 Suboptimal results have been attributed
to anthractic nodes in the thorax, a ‘‘shine-through’’ effect
(in which a high radioactive signal from the injection site
produces false-positive results because of increased back-
ground signal in nearby tissues), and distortion of critical
anatomy by blue dye.
NIR imaging has specific advantages over current SLN
mapping techniques and has proved effective in multiple
cancers, including breast, cervical, gastrointestinal, and
skin cancers.17-20 The current study confirms that NIR
imaging can be performed intraoperatively, in real time
during lung surgery, for visualization of lymph nodes
without distortion of critical intrathoracic structures, as
seen with blue dyes or the radioactive risk associated with
radioisotopes. Although only a single institutional proof-
of-concept study, at least 1 SLN was identified in all pa-
tients within the 2500-mg ICG dose cohort. Although this
early dose-escalation trial is not able to determine the role
of NIR imaging in the staging of patients with NSCLC,
we have identified a dose-response for SLN identification
and demonstrated safety and feasibility of minimallyery c September 2013
TABLE 2. SLN vs non-SLN pathology for all patients with NIR+ SLNs
Patient
no.
Tumor
location
Tumor
size, cm Tumor pathology
SLN node
station* SLN pathology IHCy
No. of node
stations
sampledz
No. of nodes
harvestedx
Non-SLN pathology
Positive Negative
6 LUL 6.0 Adenocarcinoma 4L Negative Negative 4 9 None 5, 10Ls, 11L
13 RUL 1.3 Squamous cell 10.1R
10.2R
10.3R
Negative Negative 2 6 None 10R 32,
Intraparenchymal
LNs
14 RUL 1.7 Large cell 11R Negative Negative 2 3 None 4R 32
16 RUL 2.3 Adenocarcinoma 10.1R Negative Negative 1 3 None 10R 32
23 LUL 1.6 Adenocarcinoma 10L
11L
Negative Negative 2 7 None 10L 32, 11L 33
24 RLL 4.0 Adenocarcinoma 9R Negative Negative 5 12 None 7, 8, 9 32, 10R 35,
11R 32
25 RUL 3.2 Adenocarcinoma 10.1R
11R
Negative Negative 3 6 None 4R, 10R 33
29 RUL 1.2 Sarcomatoid
carcinoma
4R Negative Insufficient
tissue
1 2 None 4R 32
30 LUL 2.6 Adenocarcinoma 9.1L
10.1L
10.1L Positive 5 14 10L and
11L 33
5 33, 7, 9L 33,11L
32 LUL 6.5 Adenocarcinoma 5
10.1L
10.1L Positive 4 20 2 of 13 Hilar
nodes
4L 33, 10L 32, 11
of 13 hilar nodes
34 LLL 1.0 Adenocarcinoma 10.1L 10.1L Positive 1 2 None 10L
35 RUL 1.1 Adenocarcinoma 4.1R
10.1R
Negative Insufficient
tissue
2 5 None 4R, 10R
36 RML 2.4 Adenocarcinoma 4R
10.1R
10.2R
10.1R and
10.2R
Positive
3 6 7
10R
10R
37 LUL 2.0 Squamous cell 10.1L
10.2L
10.1L Positive 4 8 5 32 and
7 10L, 11L
11L
38 RLL 2.9 Adenocarcinoma 11.1R
11.2R
11.2R Positive 6 14 None 4R 32, 7 32, 8, 9,
10R 35, 11R
Bold denotes positive lymph node pathology and indicates that these nodes showed metastatic disease within the respective highlighted lymph node. SLN, Sentinel lymph node;
NIR, near infrared; IHC, immunohistochemistry; LUL, left upper lobe; L, left; RUL, right upper lobe; R, right; LN, lymph node; RML, right middle lobe. *Nodes retrieved from the
same nodal station are labeled in sequential order as *.1, *.2, etc, to maintain individual specimen identity, with multiple nodes shown as 32 or33, etc. yIHC only available if
sufficient tissue available after all clinically necessary analysis performed for patient care. zNode stations sampled in addition to stations sampled via cervical mediastinoscopy,
endobronchial ultrasound, and SLN mapping. xMinimum number of nodes harvested because multiple nodes within a given station often grouped together.
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stage NSCLC. Furthermore, although the primary objective
of this trial was to establish safety and dose-response, we
have shown that SLN identification can lead to detection
of nodal metastatic disease and permit increased histologic
analysis via immunohistochemistry or other modalities,
with the goal of improving NSCLC staging.
Although the ICG dose required for intrathoracic SLN vi-
sualization is higher than that required for clinical SLN im-
aging in patients with breast cancer and melanoma, this
study reports success at significantly lower doses than
used for cardiac output measurements or other lung imag-
ing.17,20,25 Surprisingly, despite sequential doubling of the
successful ICG dose used for lung SLN mapping in swine
(ie, 10 mg), SLNs were not identified in humans at these
low doses. Similar findings in translation of NIR
technology to human patients with breast cancer resulted
in a new dose-escalation scheme starting at 100 mg, suggest-
ing that, despite the similar size of humans and large-animalThe Journal of Thoracic and Camodels, lymphatic mapping may fundamentally differ be-
tween species and organ systems. Since commencement
of our trial in 2009, our dose of ICG has increased signifi-
cantly from 3.8 to 2500 mg. The current dose of 2500 mg
is higher than the 488 mg used in NIR imaging for patients
with both melanoma and breast cancer17,20 but far less than
the 5- to 10-mg doses previously reported in Japanese stud-
ies.25 Given the reported risk, albeit rare, of anaphylaxis and
distortion of visual anatomy using high doses of ICG, our
goals were to identify a safe, optimal dose for injection
that did not alter surgical vision, yet resulted in identifica-
tion of lymphatic migration in patients with lung cancer.
We have demonstrated the dose-dependent identification
of SLN, with success at doses of 1000 to 2500 mg. Although
the sample size is small, the detection of SLN in all patients
within the 2500-mg cohort suggests that, although meta-
static disease can reach the contralateral lymph node basins,
localization of the first draining lymph node (ie, SLN) to
these contralateral nodes is likely rare. Given the absencerdiovascular Surgery c Volume 146, Number 3 567
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imen at any dose, failure to identify the SLN in 20% of pa-
tients at a dose of 1000 mg is unlikely to be the result of
SLNs being present elsewhere in the mediastinum, but cer-
tainly could be the result of inadequate ICG dose or second-
ary to ICG leakage from the intraparenchymal injection
site. We are working on methods to improve our technique
to maximize SLN detection.
Although lymphatic mappingmay be affected by the bulk
of metastatic nodal disease, the patients in this study were
specifically chosen to clinically have no evidence of nodal
disease, as evident by negative PET/CT and/or cervical me-
diastinoscopy results.26 Nonetheless, tumors of various
sizes and lobar locations were included in both high- and
low-dose ICG cohorts, given that tumor size has correlated
with the incidence of metastatic nodal disease. Similar to
previously published data for SLN biopsy specimens in pa-
tients with breast cancer,27,28 the results of the current study
did not demonstrate a relationship between positive
identification of SLNs and tumor size or location. Instead,
ICG dose was the primary factor determining the
likelihood of SLN identification in this study. However, it
was evident that there is significant variability in the
lymphatic drainage patterns from the lung tumor to SLN.
Although nearly three-quarters of the 26 NIRþ SLNs iden-
tified were located in the nearby N1 stations, a surprising
27% of patients had SLN that had ‘‘skipped’’ to an N2 sta-
tion, placing them at risk for having occult stage III disease
despite a preoperative assessment of clinical stage I disease.
This is consistent with the 20% to 30% incidence of skip
metastases reported by others using technetium 99 and
demonstrates the importance of accurately identifying the
SLN in these patients.29,30
Only 3 SLN nodes were identified in the intralobar posi-
tion (station 11), with no SLN identified in the more distal
sublobar and segmental positions. We hypothesize that this
is the result of high fluorescence at the injection site and sur-
rounding lung parenchyma, which can obscure our ability to
identify a discrete separate NIR signal higher than back-
ground within the intraparenchymal lymph node stations
(segmental and subsegmental), causing the equivalent of
a ‘‘shine effect.’’ We have decreased the impact of this by
positioning the injection site out of the visual field while
looking at the hilum and mediastinum, but this may still
be affecting our ability to image nodes closer to the tumor
itself. Second, imaging is particularly difficult if ICG leaks
from the injection site onto the nearby lung, which may
have distorted our ability to identify discrete nodes in these
lymph node stations and suggests that individual imaging of
segmental nodes dissected ex vivo from the resected speci-
men may have identified additional SLN nodes in these sta-
tions. Third, althoughNIR imaging is feasible for up to 1 cm
in depth,22 this does not appear to be the case in air-filled
lung or within the mediastinum around the bronchial568 The Journal of Thoracic and Cardiovascular Surgstructures. Having said this, final pathology has not identi-
fied metastatic nodes within the more distal segmental posi-
tions, even in those patients with metastatic SLN identified
in the level 10 or 11 nodes, indicating that the identified
NIRþ SLNs are sufficient for identification of metastatic
nodal disease.
The high incidence of mediastinal (N2) SLN and the var-
iability of SLN location between patients highlight the dif-
ficulty in predicting the site of metastatic nodal disease in
patients with NSCLC. In the current trial, despite a negative
preoperative workup via PET and possible mediastino-
scopy, 7 lymph nodes were positive for metastatic disease
on H&E staining. Therefore, although our numbers are
small, SLN analysis resulted in the upstaging of 6 of the
15 patients with NSCLC in whom SLNs were identified
in this study. This suggests that 40% of patients were under-
staged preoperatively, which is not significantly different
than the 27.5% of patients with stage I NSCLC who had
node-positive disease at resection, despite a negative preop-
erative workup, in CALGB 9761.31
Identification of the sentinel lymph node in patients with
NSCLC may allow for detailed histologic analysis via im-
munohistochemistry or polymerase chain reaction, thereby
leading to more accurate staging in NSCLC. Although im-
munohistochemical assessment of a few SLNs found to be
negative on H&E in this study has not yet identified occult
metastases, we expect that additional analysis, including
polymerase chain reaction, in a larger population will po-
tentially identify micrometastatic disease in a subset of
these H&E-negative SLNs. This may result in identification
of patients who may benefit from adjuvant therapy for pre-
viously undetected occult disease, with the goal of improv-
ing survival. Our current phase 1 trial has identified an ICG
dose-response for SLN identification and has demonstrated
the safety and feasibility of NIR imaging for SLN identifi-
cation in patients undergoing resection for NSCLC via
a minimally invasive, intraoperative approach. Although
we have demonstrated the detection of metastatic disease
within NIRþ SLNs, additional studies are needed to im-
prove SLN imaging and dose delivery, determine sensitivity
and specificity of this approach, and ultimately assess the
impact of SLN analysis on adjuvant therapy and overall out-
comes in patients with early-stage NSCLC.References
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Dr Chumy Nwogu (Buffalo, NY). I enjoyed your presentation
much. I have a few questions. What was your incidence of spillage
of the ICG during the injection and what was the averagemigration
time that you encountered?
Dr Gilmore. The spillage was a problem early on. One of the
other Japanese groups that has done this actually uses an Endoclip
following injection. We have converted to a deeper injection of
about 1 cm of ICG in the later cohorts. While we do not have
the exact statistics, we have reduced the leakage rate.
As for the migration itself, we can clearly see on the video that
we see immediate identification of our injection site. We have
modified our technique so that now we do perform ventilation
for 1 to 2 minutes to increase the lymphatic flow and then follow-
ing deflation of the lung again we can see the migration.
Dr Nwogu.What do you think prevented migration in the cases
where you were unsuccessful?
Dr Gilmore. In unsuccessful cases early on, we feel that the
dose was too low at that point; this was based on preclinical trials.
Since we have now gone to higher doses, we feel we have more
consistent and reliable imaging, and, again, in the higher doses
this may be due to spillage.
Dr Nwogu. I wonder whether the ICG stops at the first echelon
of the sentinel node or does it go beyond that? What was the aver-
age number of lymph nodes you identified per patient?
Dr Gilmore. The average was one lymph node identified per
patient. There was only a total of 13 lymph nodes in 11 patients.
There were instances where there were 2 lymph nodes identified.
We do use ICG coupled with albumin, and we have seen this in-
creases retention within the first lymph node but does not permit
further migration.
Dr David Sugarbaker (Boston, Mass). I enjoyed your presen-
tation much, and I think this has a lot of potential. I have 2 ques-
tions. Number one, what is the interoperative time required from
initial injection to the identification of the sentinel node?
Dr Gilmore. It does not add a considerable amount of time to
the procedure itself. We do perform the injection and then ventilate
for 1 to 2 minutes to allow for increased migration. Following
deflation of the lung, we are then able to identify the lymph
node readily. And I think in total it may add an additional 10
to 15 minutes to the procedure.rdiovascular Surgery c Volume 146, Number 3 569
General Thoracic Surgery Gilmore et al
G
T
SDr Sugarbaker. Actually I have 2 more questions real briefly.
Of interest, does the lung need to be inflated for optimal lymphatic
flow? You mentioned that. Is that a prerequisite or can you do it
with the lung atelectatic?
Dr Gilmore.We feel that ventilation of the lung does increase
lymphatic migration. In our earlier patients, we did use a deflated
lung, and we did not see as great a migration, and we feel that this
may be secondary to decreased lymphatic flow.
Dr Sugarbaker. And the third thing is one of the things that
concerns all of us in mapping our understanding an individual570 The Journal of Thoracic and Cardiovascular Surgpatient the lymphatic flow is crossover, particularly from lower
lobes to the contralateral 4R, so right lower lobe to 4R or right
lower lobe to 4L or left lower lobe to 4R as the first station. Do
you see in the future the ability to map both N2 and N3 stations
utilizing this technique?
Dr Gilmore. That is a good question. Currently, we do not have
that possibility, because during a normal video-assisted thoraco-
scopic surgery resection, we do not see the contralateral side,
but that is something we should consider.
Dr Sugarbaker. Thank you.ery c September 2013
